Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.67 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.67 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6322149 | 1.00 | ADRB1 (0.67) | ADRB1ADRB3ADRB2MEN1KMT2A | |
| SCHEMBL26031129 | 0.97 | ADRB1 (0.64) | ADRB1ADRB3ADRB2MEN1KMT2A | |
| SCHEMBL21759057 | 0.97 | ADRB1 (0.64) | ADRB1ADRB3ADRB2MEN1KMT2A | |
| SCHEMBL26031131 | 0.97 | ADRB1 (0.64) | ADRB1ADRB3ADRB2MEN1KMT2A | |
| SCHEMBL26031128 | 0.97 | ADRB1 (0.64) | ADRB1ADRB3ADRB2MEN1KMT2A | |
| SCHEMBL11169814 | 0.92 | MEN1 (0.65) | ADRB1ADRB3ADRB2MEN1KMT2A | |
| SCHEMBL11518076 | 0.90 | NPC1 (0.76) | ADRB1ADRB3ADRB2MEN1KMT2A | |
| SCHEMBL11606524 | 0.88 | MEN1 (0.71) | ADRB1ADRB3ADRB2MEN1KMT2A | |
| SCHEMBL11518406 | 0.86 | ADRB2 (0.70) | ADRB1ADRB3ADRB2MEN1KMT2A | |
| SCHEMBL11499125 | 0.86 | MEN1 (0.60) | ADRB1ADRB3ADRB2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10045689-A | — | — | None | — | — | JP | disclosed |
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-25 | — | — | US | disclosed |
| CN-1323289-A | Aminoalcohol derivatives and their use as beta3Use of adrenergic agonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-11-21 | — | — | CN | disclosed |
| EP-1107944-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012462-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-09 | — | — | WO | disclosed |
| JP-H1045689-A | PRODUCTION OF RS-, R-OR S-BENZYLAMINO-3-PHENOXY-2-PROPANOL | DAITO KAGAKU KK | 1998-02-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043371-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB3, ADRB2 | ADRB1 1/4885ADRB3 2/4885ADRB2 3/4885 |
| US-20030181726-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB3, ADRB2 | ADRB1 1/4885ADRB3 2/4885ADRB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.